-
公开(公告)号：WO2012091549A1
公开(公告)日：2012-07-05
申请号：PCT/NL2011/050556
申请日：2011-08-11
Applicant: N.V. NUTRICIA , HAGEMAN, Robert, Johan, Joseph , DE WILDE, Mattheus, Cornelis , GROENENDIJK, Martine , KAMPHUIS, Patrick, Joseph, Gerardus, Hendrikus
Inventor： HAGEMAN, Robert, Johan, Joseph , DE WILDE, Mattheus, Cornelis , GROENENDIJK, Martine , KAMPHUIS, Patrick, Joseph, Gerardus, Hendrikus
IPC: A61K31/14 , A61K31/202 , A61K31/355 , A61K31/375 , A61K31/4415 , A61K31/519 , A61K31/683 , A61K31/685 , A61K31/7072 , A61K31/714 , A61K33/04 , A61K45/06 , A61P3/02 , A61P21/00 , A61P25/28
CPC classification number: A61K31/675 , A23L33/12 , A23L33/13 , A23L33/15 , A23L33/40 , A23V2002/00 , A61K31/14 , A61K31/20 , A61K31/202 , A61K31/355 , A61K31/375 , A61K31/4415 , A61K31/519 , A61K31/661 , A61K31/683 , A61K31/685 , A61K31/70 , A61K31/7056 , A61K31/7068 , A61K31/7072 , A61K31/714 , A61K33/04 , A61K45/06 , C07H19/052 , C07H19/06 , A61K2300/00 , A23V2200/316 , A23V2200/322 , A23V2250/1882 , A23V2250/304 , A23V2250/704 , A23V2250/156 , A23V2250/1626 , A23V2250/1844 , A23V2250/1846 , A23V2250/1848 , A23V2250/185 , A23V2250/1852 , A23V2250/1868 , A23V2250/187 , A23V2250/5424 , A23V2250/7052 , A23V2250/7058 , A23V2250/706 , A23V2250/308
Abstract: Composition comprising at least two components, more preferably at least three com- ponents, more preferably at least four components, selected from the group of (i) a nu- cleoside equivalent, (ii) an ω-3 polyunsaturated fatty acid selected from the group of DHA, DPA and EPA, (iii) a vitamin B, (iv) a phospholipid, (v) an antioxidant and (vi) a choline, with the proviso that at least component (i) or (iii) is present, for use in the prevention or treatment of frailty in a mammal, wherein frailty is determined by com- pliance with at least 2 criterions, preferably 3 criterions, selected from the group of muscle weakness, excessive feelings of exhaustion or fatigue, abnormally low physical activity, slow or unsteady gait, weight loss, and neurological dysfunction.
Abstract translation: 组合物，其包含至少两种组分，更优选至少三种组分，更优选至少四种组分，所述组分选自（i）核苷当量，（ii）选自以下的α-3多不饱和脂肪酸 DHA，DPA和EPA组，（iii）维生素B，（iv）磷脂，（v）抗氧化剂和（vi）胆碱，条件是至少存在组分（i）或（iii） 用于预防或治疗哺乳动物的虚弱，其中通过符合从肌肉无力，疲劳或疲劳过度感觉，异常低体力活动组中选择的至少2个标准，优选3个标准来确定虚弱， 慢性或不稳定的步态，体重减轻和神经功能障碍。
-
公开(公告)号：WO2013129914A1
公开(公告)日：2013-09-06
申请号：PCT/NL2012/050129
申请日：2012-03-02
Applicant: N.V. Nutricia , LANSBERGEN, Marieke , GROENENDIJK, Martine , KAMPHUIS, Patrick Joseph Gerardus Hendrikus , DE WILDE, Mattheus Cornelis
Inventor： LANSBERGEN, Marieke , GROENENDIJK, Martine , KAMPHUIS, Patrick Joseph Gerardus Hendrikus , DE WILDE, Mattheus Cornelis
IPC: A61K31/7068 , A61K31/201 , A61K31/202 , A61K31/7072 , A61K45/06 , A61K31/14 , A61K31/355 , A61K31/375 , A61K31/4415 , A61K31/519 , A61K31/714 , A61K33/04
CPC classification number: A61K45/06 , A61K31/14 , A61K31/201 , A61K31/202 , A61K31/355 , A61K31/375 , A61K31/4415 , A61K31/519 , A61K31/7068 , A61K31/7072 , A61K31/714 , A61K33/04 , A61K2300/00
Abstract: The invention relates to a composition comprising:(i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof;and (ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA),or esters thereof, for use in preserving or improving functional synapticconnectivity in a subject in need thereof.
Abstract translation: 本发明涉及一种组合物，其包含：（i）尿苷和胞苷中的一种或多种，或其盐，磷酸酯，酰基衍生物或其酯;和（ii）包含二十二碳六烯酸（22:6; DHA ），二十碳五烯酸（20:5; EPA）和二十二碳五烯酸（22：5; DPA）或其酯，用于保存或改善有需要的受试者的功能性突触连接性。
-
公开(公告)号：WO2012091548A1
公开(公告)日：2012-07-05
申请号：PCT/NL2011/050555
申请日：2011-08-11
Applicant: N.V. NUTRICIA , DE WILDE, Mattheus, Cornelis , HAGEMAN, Robert, Johan, Joseph , GROENENDIJK, Martine , KAMPHUIS, Patrick, Joseph, Gerardus, Hendrikus
Inventor： DE WILDE, Mattheus, Cornelis , HAGEMAN, Robert, Johan, Joseph , GROENENDIJK, Martine , KAMPHUIS, Patrick, Joseph, Gerardus, Hendrikus
CPC classification number: A61K31/675 , A23L33/12 , A23L33/13 , A23L33/15 , A23L33/40 , A23V2002/00 , A61K31/14 , A61K31/20 , A61K31/202 , A61K31/355 , A61K31/375 , A61K31/4415 , A61K31/519 , A61K31/661 , A61K31/683 , A61K31/685 , A61K31/70 , A61K31/7056 , A61K31/7068 , A61K31/7072 , A61K31/714 , A61K33/04 , A61K45/06 , C07H19/052 , C07H19/06 , A61K2300/00 , A23V2200/316 , A23V2200/322 , A23V2250/1882 , A23V2250/304 , A23V2250/704 , A23V2250/156 , A23V2250/1626 , A23V2250/1844 , A23V2250/1846 , A23V2250/1848 , A23V2250/185 , A23V2250/1852 , A23V2250/1868 , A23V2250/187 , A23V2250/5424 , A23V2250/7052 , A23V2250/7058 , A23V2250/706 , A23V2250/308
Abstract: Non-medical use of at least two components selected from the group of: (i) nucleoside equivalents, (ii) n-3 polyunsaturated fatty acids selected from the group of DHA, DPA and EPA, (iii) vitamins B, (iv) phospholipids, (v) antioxidants and (vi) cholines - with the proviso that at least one (i) nucleoside or at least one (iii) vitamin B is present - for in- creasing or maintaining the body weight, for improving the ability to perform an activity of daily living of a mammal, for maintaining the ability to perform an activity of daily living of a mammal, or for reducing a deterioration in the ability to perform an activity of daily living of a mammal.
Abstract translation: 至少两种选自下组的组分的非医疗用途：（i）核苷当量，（ii）选自DHA，DPA和EPA的n-3多不饱和脂肪酸，（iii）维生素B，（iv） 磷脂，（v）抗氧化剂和（vi）胆碱 - 条件是存在至少一种（i）核苷或至少一种（iii）维生素B） - 用于增加或维持体重，用于提高 进行哺乳动物的日常生活活动，以维持进行哺乳动物的日常生活活动的能力，或降低进行哺乳动物日常生活活动能力的恶化。
-
4.发明申请
公开(公告)号：WO2012091542A1
公开(公告)日：2012-07-05
申请号：PCT/NL2010/050892
申请日：2010-12-28
Applicant: N.V. Nutricia , HAGEMAN, Robert Johan Joseph , DE WILDE, Mattheus Cornelis , GROENENDIJK, Martine , KAMPHUIS, Patrick Joseph Gerardus Hendrikus
Inventor： HAGEMAN, Robert Johan Joseph , DE WILDE, Mattheus Cornelis , GROENENDIJK, Martine , KAMPHUIS, Patrick Joseph Gerardus Hendrikus
IPC: A61K31/14 , A61K31/202 , A61K31/355 , A61K31/375 , A61K31/4415 , A61K31/519 , A61K31/683 , A61K31/685 , A61K31/7072 , A61K31/714 , A61K33/04 , A61K45/06 , A61P3/02 , A61P21/00 , A61P25/28
CPC classification number: A61K31/675 , A23L33/12 , A23L33/13 , A23L33/15 , A23L33/40 , A23V2002/00 , A61K31/14 , A61K31/20 , A61K31/202 , A61K31/355 , A61K31/375 , A61K31/4415 , A61K31/519 , A61K31/661 , A61K31/683 , A61K31/685 , A61K31/70 , A61K31/7056 , A61K31/7068 , A61K31/7072 , A61K31/714 , A61K33/04 , A61K45/06 , C07H19/052 , C07H19/06 , A61K2300/00 , A23V2200/316 , A23V2200/322 , A23V2250/1882 , A23V2250/304 , A23V2250/704 , A23V2250/156 , A23V2250/1626 , A23V2250/1844 , A23V2250/1846 , A23V2250/1848 , A23V2250/185 , A23V2250/1852 , A23V2250/1868 , A23V2250/187 , A23V2250/5424 , A23V2250/7052 , A23V2250/7058 , A23V2250/706 , A23V2250/308
Abstract: Composition comprising at least two components, more preferably at least three components, more preferably at least four components, selected from the group of (i) a nucleoside equivalent, (ii) an ω-3 polyunsaturated fatty acid selected from the group of DHA, DPA and EPA, (iii) a vitamin B, (iv) a phospholipid, (v) an antioxidant and (vi) a choline, with the proviso that at least component (i) or (iii) is present, for use in the prevention or treatment of frailty in a mammal, wherein frailty is determined by compliance with at least 2 criterions, preferably 3 criterions, selected from the group of muscle weakness, excessive feelings of exhaustion or fatigue, abnormally low physical activity, slow or unsteady gait, weight loss, and neurological dysfunction.
Abstract translation: 包含选自以下的组的至少两种组分，更优选至少三种组分，更优选至少四种组分的组合物：（i）核苷等价物，（ii）ω-3多不饱和脂肪酸 （iii）维生素B，（iv）磷脂，（v）抗氧化剂和（vi）胆碱，条件是至少组分（i）或（iii）选自DHA，DPA和EPA， ）存在，用于预防或治疗哺乳动物脆弱症，其中脆弱程度通过遵守至少2个标准，优选3个标准来确定，所述标准选自肌肉无力，过度疲劳或疲劳感，异常低 身体活动，缓慢或不稳定的步态，体重减轻和神经功能障碍。
-
公开(公告)号：WO2009002146A1
公开(公告)日：2008-12-31
申请号：PCT/NL2007/050307
申请日：2007-06-26
Applicant: N.V. NUTRICIA , GROENENDIJK, Martine , DE WILDE, Mattheus, Cornelis , HAGEMAN, Robert, Johan, Joseph , KAMPHUIS, Patrick, Joseph, Gerardus, Hendrikus
Inventor： GROENENDIJK, Martine , DE WILDE, Mattheus, Cornelis , HAGEMAN, Robert, Johan, Joseph , KAMPHUIS, Patrick, Joseph, Gerardus, Hendrikus
IPC: A61K31/20 , A23L1/29 , A23L1/30 , A23L1/304 , A23L1/305 , A61K31/14 , A61K31/202 , A61K31/7072 , A61P25/28 , A61P43/00
CPC classification number: A61K31/7072 , A23L33/10 , A23L33/12 , A23L33/15 , A23L33/40 , A61K31/14 , A61K31/202 , A61K31/4415 , A61K31/519 , A61K31/70 , A61K31/7056 , A61K38/00 , A61K45/06 , A61K2300/00
Abstract: The invention provides a method for supporting operational activities in daily living by providing a combination of (a) long-chain polyunsaturated fatty acids, particularly DHA and/or EPA, and (b) nucleosides or nucleotides, particularly uridine or its equivalent. The operational activities comprise independent housekeeping, transportation, shopping or personal hygiene activities, independent walking, bathing, grooming, dressing, use of communication equipment, use of household appliances, cleaning dishes, preparation of meal or drink or writing.
Abstract translation: 本发明提供了一种通过提供（a）长链多不饱和脂肪酸，特别是DHA和/或EPA的组合和（b）核苷或核苷酸，特别是尿苷或其等同物的组合来支持日常生活中的操作活动的方法。 经营活动包括独立的家政，交通，购物或个人卫生活动，独立散步，洗澡，梳洗，敷料，使用通讯设备，使用家用电器，清洁用具，准备餐点或饮料或书写。
-
Patent Agency Ranking
公开(公告)号：WO2014027882A1
公开(公告)日：2014-02-20
申请号：PCT/NL2012/050561
申请日：2012-08-13
Applicant: N.V. NUTRICIA , GROENENDIJK, Martine , HAGEMAN, Robert Johan Joseph , DE WILDE, Mattheus Cornelis
IPC: A61K31/14 , A61K31/202 , A61K31/7072 , A61P25/28
CPC classification number: A61K31/7072 , A61K31/14 , A61K31/202 , A61K31/4415 , A61K31/519 , A61K31/66 , A61K31/685 , A61K31/714 , A61K33/06 , A61K33/30 , A61K45/06 , A61K2300/00
Abstract: This invention pertains to the use of an uridine source, preferably uridine monophosphate,for increasing, controlling and/or maintaining fasting plasma uridine concentrations in a range of 4 to 8 µM in a subject in need thereof, comprising administering to said subject a composition comprising 300 –900 mg of said uridine source daily for a period of at least 4 weeks. In particular, the use of an uridine source is intended forelderly and/or subjects suffering from neurological disorders such as Alzheimer's Disease and dementia syndromes.
Abstract translation: 本发明涉及在有需要的受试者中使用尿苷来源，优选尿苷单磷酸，用于增加，控制和/或维持4至8μM范围内的空腹血浆尿苷浓度，包括向所述受试者施用包含 300-900mg的所述尿苷源每日至少4周。 特别地，使用尿苷来源是预期的老年人和/或患有神经障碍如阿尔茨海默病和痴呆综合征的受试者。
-
公开(公告)号：WO2012125034A1
公开(公告)日：2012-09-20
申请号：PCT/NL2012/050158
申请日：2012-03-14
Applicant: N.V. NUTRICIA , DE WILDE, Mattheus Cornelis , SIJBEN, Johannes Wilhelmus Christina , KAMPHUIS, Patrick Joseph Gerardus Hendrikus , HAGEMAN, Robert Johan Joseph
Inventor： DE WILDE, Mattheus Cornelis , SIJBEN, Johannes Wilhelmus Christina , KAMPHUIS, Patrick Joseph Gerardus Hendrikus , HAGEMAN, Robert Johan Joseph
CPC classification number: A61K31/7056 , A23D7/003 , A23D7/0053 , A23L33/115 , A23L33/13 , A23V2002/00 , A61K9/0095 , A61K31/14 , A61K31/202 , A61K31/205 , A61K31/355 , A61K31/375 , A61K31/4415 , A61K31/519 , A61K31/675 , A61K31/685 , A61K31/7068 , A61K31/7072 , A61K31/714 , A61K33/04 , A61K2300/00 , A23V2200/08 , A23V2200/322 , A23V2250/1626 , A23V2250/1868 , A23V2250/187 , A23V2250/304 , A23V2250/7052 , A23V2250/7056 , A23V2250/706 , A23V2250/708 , A23V2250/712
Abstract: The invention relates to a composition comprising: i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof, in which the lipid fraction comprises less than 2 weight% of - linolenic acid (ALA), calculated on the weight of all fatty acids; iii) choline, or salts or esters thereof; for use in the prevention or treatment of neurotrauma, traumatic brain injury, cerebral palsyand spinal cord injury.
Abstract translation: 本发明涉及一种组合物，其包含：i）尿苷和胞苷中的一种或多种，或其盐，磷酸酯，酰基衍生物或其酯; ii）包含二十二碳六烯酸（22:6; DHA），二十碳五烯酸（20:5; EPA）和二十二碳五烯酸（22：5; DPA）或其酯的至少一种的脂质部分，其中脂质部分包含 小于2重量％的α-亚麻酸（ALA），以所有脂肪酸的重量计算; iii）胆碱或其盐或酯; 用于预防或治疗神经损伤，创伤性脑损伤，脑性麻痹和脊髓损伤。
-
公开(公告)号：WO2012091571A3
公开(公告)日：2012-07-05
申请号：PCT/NL2011/050908
申请日：2011-12-28
Applicant: N.V. NUTRICIA , HAGEMAN, Robert Johan Joseph , DE WILDE, Mattheus Cornelis , GROENENDIJK, Martine , KAMPHUIS, Patrick Joseph Gerardus Hendrikus
Inventor： HAGEMAN, Robert Johan Joseph , DE WILDE, Mattheus Cornelis , GROENENDIJK, Martine , KAMPHUIS, Patrick Joseph Gerardus Hendrikus
IPC: A61K31/14 , A61K31/202 , A61K31/355 , A61K31/375 , A61K31/4415 , A61K31/519 , A61K31/683 , A61K31/685 , A61K31/7072 , A61K31/714 , A61K33/04 , A61K45/06 , A61P3/02 , A61P21/00 , A61P25/28
Abstract: Composition comprising at least two components, more preferably at least three components, more preferably at least four components, selected from the group of (i) a nucleoside equivalent, (ii) an ω-3 polyunsaturated fatty acid selected from the group of DHA, DPA and EPA, (iii) a vitamin B, (iv) a phospholipid, (v) an antioxidant and (vi) a choline, with the proviso that at least component (i) or (iii) is present, for use in the prevention or treatment of frailty in a mammal, wherein frailty is determined by compliance with at least 2 criterions, preferably 3 criterions, selected from the group of muscle weakness, excessive feelings of exhaustion or fatigue, abnormally low physical activity, slow or unsteady gait, weight loss, and neurological dysfunction.
-
9.发明申请
公开(公告)号：WO2012091571A2
公开(公告)日：2012-07-05
申请号：PCT/NL2011050908
申请日：2011-12-28
Applicant: NUTRICIA NV , HAGEMAN ROBERT JOHAN JOSEPH , DE WILDE MATTHEUS CORNELIS , GROENENDIJK MARTINE , KAMPHUIS PATRICK JOSEPH GERARDUS HENDRIKUS
Inventor： HAGEMAN ROBERT JOHAN JOSEPH , DE WILDE MATTHEUS CORNELIS , GROENENDIJK MARTINE , KAMPHUIS PATRICK JOSEPH GERARDUS HENDRIKUS
IPC: A61K31/14 , A23L1/00 , A61K31/202 , A61K31/355 , A61K31/375 , A61K31/4415 , A61K31/519 , A61K31/683 , A61K31/685 , A61K31/7072 , A61K31/714 , A61K33/04 , A61K45/06 , A61P3/02 , A61P21/00 , A61P25/28 , A61P43/00
CPC classification number: A61K31/675 , A23L33/12 , A23L33/13 , A23L33/15 , A23L33/40 , A23V2002/00 , A61K31/14 , A61K31/20 , A61K31/202 , A61K31/355 , A61K31/375 , A61K31/4415 , A61K31/519 , A61K31/661 , A61K31/683 , A61K31/685 , A61K31/70 , A61K31/7056 , A61K31/7068 , A61K31/7072 , A61K31/714 , A61K33/04 , A61K45/06 , C07H19/052 , C07H19/06 , A61K2300/00 , A23V2200/316 , A23V2200/322 , A23V2250/1882 , A23V2250/304 , A23V2250/704 , A23V2250/156 , A23V2250/1626 , A23V2250/1844 , A23V2250/1846 , A23V2250/1848 , A23V2250/185 , A23V2250/1852 , A23V2250/1868 , A23V2250/187 , A23V2250/5424 , A23V2250/7052 , A23V2250/7058 , A23V2250/706 , A23V2250/308
Abstract: Composition comprising at least two components, more preferably at least three components, more preferably at least four components, selected from the group of (i) a nucleoside equivalent, (ii) an ?-3 polyunsaturated fatty acid selected from the group of DHA, DPA and EPA, (iii) a vitamin B, (iv) a phospholipid, (v) an antioxidant and (vi) a choline, with the proviso that at least component (i) or (iii) is present, for use in the prevention or treatment of frailty in a mammal, wherein frailty is determined by compliance with at least 2 criterions, preferably 3 criterions, selected from the group of muscle weakness, excessive feelings of exhaustion or fatigue, abnormally low physical activity, slow or unsteady gait, weight loss, and neurological dysfunction.
Abstract translation: 包含至少两种组分，更优选至少三种组分，更优选至少四种组分的组合物，所述组分选自（i）核苷等价物，（ii）选自以下的α-3多不饱和脂肪酸：DHA， DPA和EPA，（iii）维生素B，（iv）磷脂，（v）抗氧化剂和（vi）胆碱，条件是至少存在组分（i）或（iii），用于 预防或治疗哺乳动物脆弱症，其中脆弱性通过依从至少2个选自肌肉无力，过度疲惫或疲劳感觉，异常低体力活动，步态缓慢或不稳定的标准的至少2个标准，优选3个标准来确定， 体重减轻和神经功能障碍。
-
公开(公告)号：WO2009002163A1
公开(公告)日：2008-12-31
申请号：PCT/NL2008/050406
申请日：2008-06-20
Applicant: N.V. Nutricia , GROENENDIJK, Martine , DE WILDE, Mattheus Cornelis , HAGEMAN, Robert Johan Joseph , KAMPHUIS, Patrick Joseph Gerardus Hendrikus
Inventor： GROENENDIJK, Martine , DE WILDE, Mattheus Cornelis , HAGEMAN, Robert Johan Joseph , KAMPHUIS, Patrick Joseph Gerardus Hendrikus
IPC: A23L1/29 , A23L1/30 , A23L1/304 , A23L1/305 , A61K31/14 , A61K31/202 , A61K31/7072
CPC classification number: A61K31/7072 , A23L33/10 , A23L33/12 , A23L33/15 , A23L33/40 , A61K31/14 , A61K31/202 , A61K31/4415 , A61K31/519 , A61K31/70 , A61K31/7056 , A61K38/00 , A61K45/06 , A61K2300/00
Abstract: The invention provides a method for supporting operational activities in daily living by providing a combination of (a) long-chain polyunsaturated fatty acids, particularly DHA and/or EPA, and (b) nucleosides or nucleotides, particularly uridine or its equivalent. The operational activities comprise eating; walking; toileting; bathing; grooming; dressing; u se of communication equipment; making conversations; keeping appoint ments; use of household appliances; cleaning dishes; preparation of meal or drink; writing; reading; independent housekeeping; transportation and shopping.
Abstract translation: 本发明提供了一种通过提供（a）长链多不饱和脂肪酸，特别是DHA和/或EPA的组合和（b）核苷或核苷酸，特别是尿苷或其等同物的组合来支持日常生活中的操作活动的方法。 营业活动包括吃饭; 步行; 如厕; 洗澡; 疏导; 敷料; 我的通讯设备; 进行对话 保留任命 使用家用电器; 清洗菜肴; 准备饮食或饮料; 写作; 读; 独立家政 交通和购物。
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.021 seconds)
